Predictors of poor seroconversion and adverse events to SARS-CoV-2 mRNA BNT162b2 vaccine in cancer patients on active treatment.

MLA

Buttiron Webber, Tania, et al. “Predictors of Poor Seroconversion and Adverse Events to SARS-CoV-2 MRNA BNT162b2 Vaccine in Cancer Patients on Active Treatment.” European Journal of Cancer (Oxford, England : 1990), vol. 159, Dec. 2021, pp. 105–12. EBSCOhost, https://doi.org/10.1016/j.ejca.2021.09.030.

APA

Buttiron Webber, T., Provinciali, N., Musso, M., Ugolini, M., Boitano, M., Clavarezza, M., D’Amico, M., Defferrari, C., Gozza, A., Briata, I. M., Magnani, M., Paciolla, F., Menghini, N., Marcenaro, E., De Palma, R., Sacchi, N., Innocenti, L., Siri, G., D’Ecclesiis, O., … DeCensi, A. (2021). Predictors of poor seroconversion and adverse events to SARS-CoV-2 mRNA BNT162b2 vaccine in cancer patients on active treatment. European Journal of Cancer (Oxford, England : 1990), 159, 105–112. https://doi.org/10.1016/j.ejca.2021.09.030

Chicago

Buttiron Webber, Tania, Nicoletta Provinciali, Marco Musso, Martina Ugolini, Monica Boitano, Matteo Clavarezza, Mauro D’Amico, et al. 2021. “Predictors of Poor Seroconversion and Adverse Events to SARS-CoV-2 MRNA BNT162b2 Vaccine in Cancer Patients on Active Treatment.” European Journal of Cancer (Oxford, England : 1990) 159 (December): 105–12. doi:10.1016/j.ejca.2021.09.030.